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Allison Golden1†, Dunia Faulx1†, Michael Kalnoky1†, Eric Stevens1, Lindsay Yokobe1, Roger Peck1,
Potochoziou Karabou2, Méba Banla3, Ramakrishna Rao5, Kangi Adade2, Richard G. Gantin3, Kossi Komlan3,
Peter T. Soboslay3,4, Tala de los Santos1 and Gonzalo J. Domingo1*
Abstract
Background: Diagnostics provide a means to measure progress toward disease elimination. Many countries in
Africa are approaching elimination of onchocerciasis after successful implementation of mass drug administration
programs as well as vector control. An understanding of how markers for infection such as skin snip microfilaria
and Onchocerca volvulus-specific seroconversion perform in near-elimination settings informs how to best use these
markers.
Methods: All-age participants from 35 villages in Togo were surveyed in 2013 and 2014 for skin snip Onchocerca
volvulus microfilaria and IgG4 antibody response by enzyme-linked immunosorbent assay (ELISA) to the Onchocerca
volvulus-specific antigen Ov16. A Gaussian mixture model applying the expectation-maximization (EM) algorithm
was used to determine seropositivity from Ov16 ELISA data. For a subset of participants (n = 434), polymerase chain
reaction (PCR) was performed on the skin snips taken during surveillance.
Results: Within the 2,005 participants for which there was Ov16 ELISA data, O. volvulus microfilaremia prevalence
and Ov16 seroprevalence were, 2.5 and 19.7 %, respectively, in the total population, and 1.6 and 3.6 % in children
under 11. In the subset of 434 specimens for which ELISA, PCR, and microscopy data were generated, it was found
that in children under 11 years of age, the anti-Ov16 IgG4 antibody response demonstrate a sensitivity and
specificity of 80 and 97 %, respectively, against active infections as determined by combined PCR and microscopy
on skin snips. Further analysis was performed in 34 of the 35 villages surveyed. These villages were stratified by
all-age seroprevalence into three clusters: < 15 %; 15–20 %; and > 20 %. Age-dependence of seroprevalence for
each cluster was best reflected by a two-phase force-of-infection (FOI) catalytic model. In all clusters, the lower of
the two phases of FOI was associated with a younger age group, as reflected by the seroconversion rates for each
phase. The age at which transition from lower to higher seroconversion, between the two phases of FOI, was found
to be highest (older) for the cluster of villages with < 15 % seroprevalence and lowest (younger) for the cluster with
the highest all-age seroprevalence.
Conclusions: The anti-Ov16 IgG4 antibody response is an accurate marker for active infection in children under
11 years of age in this population. Applying Ov16 surveillance to a broader age range provides additional valuable
information for understanding progression toward elimination and can inform where targeted augmented
interventions may be needed. Clustering of villages by all-age sero-surveillance allowed application of a biphasic
FOI model to differentiate seroconversion rates for different age groups within the village cluster categories.
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Background
Onchocerciasis or “river blindness” is a neglected trop-
ical disease caused by infection with the parasitic nema-
tode Onchocerca volvulus (Ov). The disease affects
approximately 37 million people in Africa and the
Americas; more than 500,000 people are visually
impaired and 250,000 people are blinded by the disease,
with the majority of the disease burden in Africa [1–5].
The donation of the anti-parasitic medicine ivermectin,
by Merck (Kenilworth, New Jersey, USA), has enabled
the development of large mass drug administration
(MDA) programs to reduce the burden of the disease.
MDA combined with vector control has been successful
in reducing transmission to elimination in the Americas
[6–8]. Similar trends have been observed in foci in
Africa resulting from large-scale implementation of
vector control and MDA by the Onchocerciasis Control
Program (OCP) and the African Program for Onchocer-
ciasis Control (APOC) [9–13].
Monitoring progression to elimination requires meas-
uring parasite presence (or confirming absence) in the
vector and in the host as a means to confirm reduction
in parasite transmission to below sustainable levels. In
2001 the Onchocerciasis Elimination Program for the
Americas published guidelines for certification of elimin-
ation [14]. In these guidelines, the entomological thresh-
old for declaring interruption of transmission is an
upper bound of the 95 % confidence interval for preva-
lence of vectors carrying Ov infective-stage larvae L3 of
less than 1/2,000 per endemic community, and the hu-
man threshold is a five-year cumulative incidence rate of
infection of less than one case per 1,000 susceptible chil-
dren, which can be demonstrated by skin snip micros-
copy, polymerase chain reaction, or immunological
assays. Several markers for infection have been used for
mapping, measuring disease burden, and certifying elim-
ination, but many questions remain how to best use
these markers in settings approaching elimination [15–
17]. Skin snips are relatively insensitive when microfilar-
ial (MF) skin densities are low. Polymerase chain
reaction (PCR) of the skin snips may provide greater
sensitivity but still require sampling skin snips [17–20].
Screening tests using skin snip samples is challenging to
implement at large scale due to the relatively labor-
intensive nature of the process, the invasiveness, and as
local disease burden decreases, a lowered acceptability
from the community to be subjected to this process. A
transdermal patch that delivers diethylcarbamazine as a
local microfilaricide that induces a local skin reaction (a
Mazzotti reaction) also can be used as a marker for in-
fection [13, 21, 22].
Serological markers are widely used to determine ex-
posure to a disease. The most developed and advanced
serological marker for exposure to onchocerciasis is
IgG4 response to the O. volvulus marker Ov16 anti-
gen that is expressed by the larval stages (L3 and L4)
of the parasite [23]. In the Americas, the immuno-
logical assay measuring anti-Ov16 IgG4 seroconver-
sion by enzyme-linked immunosorbent assay (ELISA)
in children has been used widely to demonstrate
interruption of transmission [7, 24, 25]. In Africa,
increasingly the anti-Ov16 marker is used to confirm
interruption of transmission in foci that received
extensive rounds of MDA [6, 9, 12, 26]. The anti-
Ov16 IgG4 assay is transferable to the nitrocellulose
rapid diagnostic test (RDT) platform [27–29] and is
now commercially available (Alere SD BIOLINE On-
chocerciasis IgG4 Rapid Test, Suwon, Republic of
Korea). The availability of the assay on a point-of-
care RDT platform and the development of reagents
to facilitate in-country training and support quality
assurance greatly enhance the operational utility of
the assay for surveillance activities post-MDA as well
as possibly for monitoring progression toward elimin-
ation and mapping purposes [30].
In West Africa many countries, including Togo,
under the Onchocerciasis Control Program (OCP)
launched in 1974, successfully controlled onchocercia-
sis, initially through intensive vector control and sub-
sequently through MDA with ivermectin [31–34]. In
some countries, such as Mali and Senegal, elimination
appears feasible [35, 36]. Foci in Togo that have re-
ceived over 20 rounds of ivermectin appear also to be
achieving elimination. The ability to identify regions
that have been less successful at blocking transmis-
sion, despite intensive vector control as well as the
multiple rounds of ivermectin, will be important to
informing where and how to focus interventions. Un-
derstanding how the currently available markers for
infection can be used in this context is important.
Despite the broad utilization of the Ov16 serological
marker in the Americas and even in Africa to con-
firm no ongoing transmission through serological
surveys with children, there are very little cross-
sectional, all-age anti-Ov16 data. All-age data allow
the assessment of Ov16 endemicity over time by
application of force of infection (FOI) analysis. This
analysis is a simple reversible catalytic conversion
model that implements an estimate for rate of infec-
tion, seroconversion, and seroreversion [37]. This
study describes Ov16 serological data collected in
Togo in the years 2013 and 2014 across 34 communi-
ties and spanning all ages above five years of age.
Serological data are compared to microfilaria detec-
tion by microscopy and, for a subset of specimens,
PCR. Serological data were analyzed using FOI
models age- and village prevalence-dependent param-
eters of seroprevalence.
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Methods
Surveillance studies in Togo
Two studies were performed in Togo to determine Ov16
seroprevalence by ELISA from dried blood spots (DBS)
and to evaluate early prototype versions of an Ov16
RDT. Both studies were performed during routine
onchocerciasis surveillance during the early rainy season
just prior to annual MDA: June 4 to July 1, 2013 and
May 11 to June 16, 2014. The studies were performed by
staff members of the Togo National Program for Oncho-
cerciasis (PNLO) and the Laboratory for Onchocerciasis
Research (LRO). For each study, the staff received a two-
day training course for performing study procedures in-
cluding appropriate consent, data management, and util-
izing the dried-down recombinant positive control [30].
In addition, a research team member was present for the
first several hundred study participants to monitor test
use and to provide ongoing support. Briefly, in the 2013
study, study participants were recruited in 15 villages
over a period of 27 days, and in the 2014 study, in 20
villages over a period of 35 days.
Collection of dried blood spots for Ov16 ELISA
Following consent, study participants were given a
finger prick and resulting blood was collected on
Whatman 903 Protein Saver Cards (GE Healthcare,
Pittsburgh, PA, USA). The cards were stored in
resealable mylar pouches (ten cards per pouch)
containing two-unit clay desiccant packets (Desiccare,
Reno, NV, USA) and a humidity indicator card. Dried
blood spots (DBS) were returned to the LRO within
14 days of collection and stored at 4 °C until handled
for ELISA.
Microfilaria status of each study participant was
determined by microscopy of two corneoscleral
punches (Holth- or Walser-type) of the skin collected
from the right and left iliac crest and was conducted
by the National Onchocerciasis Control Programme
of Togo. Skin biopsies were immediately placed on
flat-bottom glass slides and incubated in 0.1 ml
physiological saline solution; after 30 min, each biopsy
was examined microscopically and the emerged
microfilariae of O. volvulus counted. After micros-
copy, the examined skin biopsies and saline were
transferred individually into a single round-bottom
well of a 96-well plate, submerged in saline solution,
and after overnight incubation at room temperature;
each biopsy was re-examined as described above.
Final counts of O. volvulus MF/mg were recorded.
Following microscopy, skin punches were returned to
the LRO in Sokode, transferred with saline to 1.5-ml
microcentrifuge tubes, sealed, and stored at -20 °C in
the saline buffer until later use in PCR.
Ov16-positive control DBS for ELISA
A solution of 250 ng/ml anti-Ov16 positive control anti-
body in fetal bovine serum (FBS) was prepared by dilu-
tion of a stock solution of 1 mg/ml anti-Ov16
recombinant IgG4 clone AbD19432_hIgG4 in 1X phos-
phate buffered saline (PBS), pH 7.4 (Bio-Rad AbD
Serotec, Puchheim, Germany) into FBS (Invitrogen,
Grand Island, NY, USA). Blood samples containing the
anti-Ov16 positive control antibody were made by
mixing the solution of 250 ng/ml thoroughly at a 1:1
dilution with packed, washed, red blood cells, and 75 μl
per circle marking of the contrived whole blood sample
was spotted on Whatman 903 Protein Saver Cards (GE
Healthcare). These cards were dried overnight in ambi-
ent laboratory conditions and then stored at -20 °C with
approximately ten cards per sealed mylar pouch contain-
ing two-unit clay desiccant packets (Desiccare, Reno,
NV, USA).
Horseradish-peroxidase (HRP)-developed ELISA for Ov16
IgG4 in DBS
DBS cards were punched using a 6-mm punch in a
blood-saturated region and punches were arrayed into a
round-bottom 96-well microtiter plate. Remaining card
material was returned to the desiccant pouch and stored
at 4 °C. One punch of positive control DBS containing
250 ng/ml Ov16 positive control was included for each
plate eluted. Each punch was eluted overnight at 4 °C in
200 μl of PBS + 0.05 % Tween-20 (PBST) + 2 % (w/v) dry
milk powder (Mix’n Drink, Saco, Middleton, WI, USA).
The solution was mixed gently before use in ELISA. For
Ov16 ELISA, 100 μl of 5 μg/ml Ov16 antigen diluted in
PBS, pH 7.4 (Sigma Chemical Company, St. Louis, MO,
USA) was added to plate wells, Immulon 2HB (Fisher
Scientific, Pittsburgh, PA, USA) [30]. For the
glutathione-S-transferase (GST) ELISA, 100 μl of 2 μg/
ml GST protein (Thermo Fisher, Waltham, MA, USA)
was added to plate wells. Plates were then covered and
stored overnight at 4 °C. The following morning, plates
were blocked with PBST + 5 % FBS (FBS - Invitrogen) at
37 °C. Plates were washed three times with PBST (Sigma
Chemical Company, St. Louis, MO, USA) and 50 μl of
DBS sample eluate was added without dilution to the
plate wells. Each eluted punch supplied two replicate
wells in the Ov16 ELISA and one well in the GST
ELISA. Samples were incubated at 37 °C for one hour,
then washed three times with PBST. A 1:5,000 dilution
of an anti-human IgG4 (6025 clone Hybridoma Reagent
Labs, Baltimore, MD, USA) was added at 50 μl per well.
Plates were incubated at 37 °C for one hour, and washed
four times with PBST. A 1:10,000 dilution of an HRP-
conjugated goat anti-mouse antibody (Jackson Immuno
Research Labs, West Grove, PA, USA) was added at
50 μl per well. Plates were incubated at 37 °C for one
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hour and then washed four times with PBST. One
hundred μl of TMB (Sigma) solution was added to each
well. Plates were incubated at room temperature for
15 min and then the reaction was stopped by adding
50 μl per well of 1 N HCl (Thermo Fisher). Plates were
read at 450 nm.
Polymerase chain reaction (PCR) of skin snips
For DNA extraction, the skin biopsies from field surveil-
lance were removed from -20 °C storage and transferred
to microcentrifuge tubes. Biopsies were processed using
the Qiagen DNA Investigator kit (Qiagen, Hilden,
Germany) according to the Tissues protocol, digesting
the skin with proteinase K overnight at 56 °C. Three elu-
tions, of 60 μl each, were performed. The eluted DNA
concentration for each sample was determined by
absorbance at 260 nm and DNA was stored at -20 °C be-
fore PCR analysis. Extracted skin biopsy DNA concen-
trations ranged from 4 ng/μl to 166 ng/μl. Real-time
PCR primers and probe used were the following:
OvFWD 5'-TGT GGA AAT TCA CCT AAA TAT G-3',
OvREV 5'-AAT AAC TGA TGA CCT ATG ACC-3',
OvProbe 5'-6FAM-TAG GAC CCA ATT CGA ATG
TAT GTA CCC-MGBNFQ-3' (minor groove binding
TaqMan® Probe #5208995 P/N 4316033, Applied Biosys-
tems, Thermo Fisher) (R. Rao, unpublished data).
Primers and TaqMan probe sequences were designed to
amplify a fragment of O. volvulus repeat DNA (0–
150 bp, GenBank acc. number: J04659.1) using Beacon
DesignerTM from PREMIER Biosoft (Palo Alto, CA,
USA). Taqman Universal PCR Master Mix (Applied Bio-
systems, P/N 4304437) and nuclease-free water were
used with all reactions with the following concentrations
and volumes: 2.5 μl of 20 μM OvFWD, 2.5 μl of 20 μM
OvREV primer, 1.5 μl of 9.2 μM OvProbe, 27.5 μl of 2×
Master Mix, 50 ng of template DNA from extracted skin
biopsies, or 1 μl Ov150 positive control plasmid at
10 ng/μl (GenBank acc. number J04659.1), or 1 ng of
genomic DNA isolated from adult O. volvulus, and
nuclease-free water was added up to a final volume of
55 μl. Reactions (2 × 25 μl per well) were run with the
following cycling conditions: 50 °C for 2 min, 95 °C for
10 min, (95 °C for 15 s, 49 °C for 30 s, 60 °C for 2 min) ×
40 cycles.
Skin snips from participants in the 2013 study were
run in single wells and analyzed using the Applied
Biosystems 7300 Real Time PCR System (96-well for-
mat), SDS version 1.4 software. Skin snips from par-
ticipants in the 2014 study were run in duplicate and
analyzed using the Corbett Rotor Gene RG-300, ver-
sion 6 software. Skin snip-derived DNA samples
producing a Ct value of less than 29, in duplicate,
were considered to be positive for presence of O.
volvulus DNA.
Statistical data analysis and modelling
Ov16 ELISA replicate optical density (OD) values were
subjected to quality control criteria for plate control
quality, sample replicate quality, and relative ELISA re-
activity with the GST protein. Quality control steps were
performed separately for each year’s dataset. Quality
control requirements were as follows in order for speci-
men results to be included in the final dataset: all plates’
positive control OD values were within 1.5× of inter-
quartile range (IQR) of the total dataset’s respective con-
trols. If a plate was excluded, samples within that plate
were also excluded and when possible, the plate was re-
peated. For individual specimens, the relative difference
(replicate difference divided by mean of the replicates) of
replicate OD values had to be less than 1.5× IQR of all
specimen relative differences. The companion GST
ELISA results were less than 1.5× IQR of all GST ELISA
OD values. Those with significantly high GST values (>
1.5× IQR) were classified as those for which cross re-
activity with GST tag on the recombinant Ov16 antigen
could not be excluded and they were not included in the
final analysis. For all specimens which had acceptable
Ov16 ELISA data, the mean OD of the Ov16 ELISA rep-
licates was normalized to the respective plate positive
control OD and the 2013 and 2014 datasets were then
combined. A univariate expectation maximization (EM)
algorithm was applied to the normalized Ov16 ELISA
dataset OD measurements characterizing the two sub-
populations in the data as either Ov16 positive or nega-
tive. The EM algorithm was set to model the normalized
distribution of OD measurements with two Gaussian
curves, producing mixing probabilities of 0.79 and 0.21,
means of 0.10 and 1.01, and variances of 0.002 and 0.825
for negative and positive distributions, respectively.
Force of infection analysis was applied by fitting the
seroprevalence as determined by Ov16 ELISA to a re-
versible catalytic model [37, 38], as stratified by age and
village prevalence ranges. Errors for estimates of preva-
lence by age were assumed to be binomially distributed.
Optimal fitting to empirical data occurs of the FOI
model and parameters lambda (seroconversion) and rho
(seroreversion) were calculated using maximum likeli-
hood techniques [39].
Results
Study demographics and microfilaremia
Surveillance activities were performed in 2013 and 2014
in Togo in 35 onchocerciasis-endemic villages, just prior
to annual MDA. Thus the study participants had all re-
ceived their previous dose of ivermectin over 11 months
ago. Longitudinal MDA and vector control data were
not available for all villages, but out of 15 villages for
which the data were available, five villages had received
MDA since 1992 and ten since 1997. All of them had
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received intensive vector-control interventions. During
the surveillance activities, skin snip microscopy was per-
formed on the same day and repeating at 24 h. DBS
were collected for Ov16 ELISA. The same skin snips
used for microscopy were preserved for PCR. A total of
2,927 study participants were recruited and provided
skin snip and DBS samples (1,456 participants in 2013
and 1,471 in 2014). Overall 56 % of the study partici-
pants were female. The summary of the demographics
and the number of MF-positive cases by age group is
shown in Table 1.
Ov16 ELISA
Exposure to onchocerciasis was assessed by HRP Ov16
ELISA for O. volvulus antigen Ov16-specific IgG4 in
dried blood spots. The recombinant Ov16 is expressed
as a GST fusion protein. A GST IgG4 ELISA was also
performed on all specimens to screen for the possibility
of misclassification due to IgG4 antibody binding to the
GST tag on the recombinant Ov16 antigen. HRP Ov16
ELISA and GST ELISA were performed on 1,099 speci-
mens from the 2013 study and 1,449 specimens from
the 2014 study. The plates and data set were subjected
to a series of quality control steps to form the consoli-
dated dataset (Fig. 1): (i) total number of specimens
excluded based on significantly high GST ELISA OD =
228 (9 %); (ii) total number of specimens excluded based
on outlier plate control OD = 32 (1 %); and (iii) total
number of specimens excluded based on exceeding spe-
cimen replicate OD relative difference = 283 (12 %).
After all processing, there were ELISA results for a total
of 2,005 specimens (Table 1 and Fig. 1).
Sero-status classification and Ov16 seroprevalence
A dichotomous classification of the combined normal-
ized Ov16 ELISA dataset was performed using an EM
mixture model (Fig. 2). The EM method categorized
specimens as ELISA-positive (395 samples) or ELISA-
negative (1,610 samples), which were then considered to
be seropositive or seronegative, respectively. Seropositive
prevalence across all age groups was calculated to be
19.7 %.
Overall, the prevalence increased with age, with
children under the age of 11 having a seroprevalence of
3.6 % (Fig. 3). One village had only two specimens’ Ov16
ELISA results. Therefore this village was excluded for
further analysis and only 2,003 specimens from 34 of the
villages were used for further analysis of seroprevalence
at individual- and clustered-village level. At the individ-
ual village level, the seroprevalence across all age groups
ranged from 5 to 54 %. Seroprevalence for children
Table 1 Study demographics broken out by age, total recruitment and number of participants included in the seroprevalence data
analysis
Age range Participants recruited Participants with Ov16 IgG4 ELISA results
Total Microfilaria (MF)-positive (prevalence in %) Total Microfilaria (MF)-positive (prevalence in %)
Ages 5–10 280 3 (1.1) 193 3 (1.6)
Ages 11–20 528 5 (1.0) 386 3 (0.8)
Ages 21–30 491 18 (3.7) 352 11 (3.1)
Ages 31–40 501 25 (5.0) 320 10 (3.1)
Ages 41–50 445 23 (5.2) 293 13 (4.4)
Ages 51–60 287 10 (3.5) 197 4 (2.0)
> 60 years of age 391 9 (2.3) 264 6 (2.3)
Total no. of participants 2,923 93 (3.1) 2,005 50 (2.5)
% female 56 (n = 1,646) 48.4 (n = 93) 58 (n = 1,155) 48 (n = 24)
No. of villages 35 35
Fig. 1 Quality control (QC) selection of specimens used in final
analysis for serological response to the Ov16 antigen. Number of
study participants are indicated at the top of the figure for the study
performed in 2013 and the study performed in 2014 on the left and
right, respectively. Progressing top to bottom, the number of
specimens used in the ELISA and then remaining after each QC step
are indicated
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under 11 years of age at an individual village level was
not calculated due the low number of children under
11 years recruited in each village.
To support additional stratification of the results, K-
means clustering was used to cluster the villages’ preva-
lence into three groups; < 15 %, 15–20 % and 21–55 %.
The prevalence levels and locations of the villages are
shown in Fig. 4. To compare all-age and < 20 years of
age groups, seroprevalence and MF-positive prevalence
were calculated for the different age group (Fig. 4b, full
data set provided in Additional file 1: Table S1). Of the
34 villages included in the analysis, 22 (64 %) no MF-
positive specimens were found, and in 29 (85 %) of the
villages there was no microfilaridermia observed in the
population under 20 years of age.
Among the anti-Ov16 ELISA positive specimens (n =
393), the normalized ODs (defined as specimen OD
divided by plate positive control OD) were compared
across village prevalence clusters and age groups and
between MF positive and MF negative (Fig. 5).
Fig. 2 a Histogram of normalized absorbance (OD) for horseradish peroxidase (HRP) Ov16 enzyme-linked immunosorbent assay (ELISA) data for
participants with Ov16 ELISA results (n = 2,005). b Density profile for HRP Ov16 ELISA data used for the expectations maximization (EM) mixture
model. c Classification of specimens for seropositivity resulting from the EM model: 1 represents seropositive, 2 represents seronegative.
d Uncertainty profile from EM specimens
Fig. 3 Ov16-specific IgG4 seroprevalence (circles) and microfilaria
prevalence (squares) against age groups, for study participants with
Ov16 ELISA results (n = 2,005)
Golden et al. Parasites & Vectors  (2016) 9:338 Page 6 of 12
Fig. 4 a Geographical distribution of villages surveyed; size and color intensity is related to the all-age Ov16 ELISA-positive seroprevalence.
b Color-coded clustering of villages showing: left of center axis, seroprevalence across all age groups, and right of center axis, seroprevalence
for study participants < 20 years of age. The seroprevalence for each age group is aligned side-by-side by village. The microfilaria (MF)-positive
prevalences for the villages are shown by the red lines for the respective age groups. Village name and numerical values are provided in
Additional file 1: Table S1
Fig. 5 Box plots for normalized anti-Ov16 IgG4 ELISA ODs for different subgroups of ELISA-positive subjects (n = 393), as determined by expectation
maximization (EM). The solid lines represent median values, the boxes the 25–75 percentiles, and whiskers the minimum to maximum range. Graph
a shows data for the≤ 15 %, 15–20 % and > 20 % seroprevalence community clusters; b shows data across age ranges (age ranges were selected
statistically based on sample distribution); and c shows microfilaria (MF)-positive and MF-negative subgroups
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Specimens from villages in the cluster with the highest
Ov16 antibody prevalence had a higher normalized anti-
Ov16 signal overall than the villages with a prevalence
of < 15 % (t = -3.6754, df = 2.5.11, P < 0.01), and 15–20 %
(t = -2.7173, df = 208.48, P < 0.01). There was no statis-
tical difference in normalized anti-Ov16 signal among
the two lower-prevalence clusters. There was no statis-
tical difference in normalized anti-Ov16 signal between
age range categories. However, the normalized anti-Ov16
ELISA signal was overall higher in MF-positive specimens
than in MF-negative specimens (t = -2.7338, df = 37.90, P
< 0.01).
Seroconversion and seroreversion rate estimations
Two age-dependent FOI curves were fitted each to the
three village prevalence-based clusters identified above.
The lower of the two phases of FOI is associated with a
younger age group, as reflected by the seroconversion
rates for each phase (Table 2). The age at which the opti-
mal transition was found between the two phases of
FOI, was highest (older) for the cluster of villages with <
15 % seroprevalence and lowest (younger) for the cluster
with the highest all-age seroprevalence, indicating that
the state of lower seroconversion occurs in a larger age
range for lower-prevalence villages. The bin widths were
chosen to keep the bin sizes and numbers equivalent to
reduce error of the fitting and allow comparisons be-
tween the different cluster FOI models. Fig. 6 shows the
best fits for FOI for the seven different age-binned
values of Ov16 prevalence for each cluster of villages.
Table 2 summarizes the age ranges for the optimal two
FOI curve fits and seroconversion rates for the three dif-
ferent clusters shown in Fig. 6.
Active infection status by microfilaria status and PCR
PCR was performed on 434 skin snips including 43 skin
snips positive for microfilaria by microscopy from a sub-
set of the 2,003 study participants for which there was
Ov-16 ELISA data. In this subset, 52 samples were found
to be positive by PCR, and PCR and MF microscopy co-
incided in 30 samples, representing 69.8 % of the 43 skin
snip microscopy-positive specimens and 57.7 % of the
52 PCR-positive specimens. Combined, a total of 65
specimens were positive by either PCR or microscopy,
such that PCR or skin snip microscopy alone detected
80 % (0.95 CI: 68–88 %) or 66 % (0.95 CI: 53–77 %),
respectively, of the combined laboratory-confirmed
active infections.
Of the 65 confirmed active infections, 39 (60 %) were
positive for Ov16 IgG4 (Table 3). The sensitivity and
specificity for Ov16 IgG4 against active infection were
60 % (0.95 CI: 48–71 %) and 75 % (0.95 CI 71–79 %). In
this subset, there were 38 specimens from children
under the age of 11, five of which were positive either by
PCR or MF. For this set of 38 specimens, the sensitivity
and specificity of Ov16 IgG4 were 80 % (0.95 CI 28–
99 %) and 97 % (0.95 CI 84–100 %), respectively. Both
the sensitivity and specificity as a marker for active in-
fection drop as the age range included in their determin-
ation is increased (data not shown).
Discussion
In this near-elimination setting, the average total micro-
filaria counts per MF-positive participant was 12 (range
0–131) and the median was 4, with over 70 % of total
microfilaria counts at less than ten counts across both
biopsies per participant. More infections were detected
by real-time PCR targeting the O. volvulus O-150 repeat
sequence [18, 19, 40, 41] than by MF by skin snip mi-
croscopy, suggesting that PCR is more sensitive to detect
active infections, as previously shown [19]. Respective
sensitivities for the PCR and skin snip microscopy com-
pared to the composite PCR/MF microscopy positive
results, are 80 and 66 %. Some microscopy-positive spec-
imens were not detected by PCR, possibly as a result of
using the same residual skin biopsies, which may have
lost target DNA or MF through handling. All MF-
positives which were missed by PCR had low (< 10)
overall combined counts of MF, and the majority had
only one or two MF observed, between both biopsies.
Our sampling for the PCR analysis was biased, so
relative prevalence data are not discussed.
Performance of Ov-16 IgG4 response as a marker for
infection was determined using combined PCR-positive
and/or MF-positive result as a true positive within the
PCR tested samples set. Anti-Ov16 antibody as a marker
for active infection, as opposed to (current and previous)
exposure to infection, in this population’s study participants
Table 2 Anti-Ov16 IgG4 seroconversion rates resulting from the reverse catalytic model fits for each age group with each village




1st FOI fit 2nd FOI fit
Age range (years) Seroconversion rate (lambda) Age range (years) Seroconversion rate (lambda)
≤ 15 % 5–25 0.0026 > 25 0.01
> 15–20 % 5–20 0.0051 > 20 0.02
> 20 % 5–16 0.0071 > 16 0.02
The age ranges also indicate the optimal point of transition from the first force-of-infection (FOI) fit to the second FOI fit (ages 25, 20, and 16)
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that were children < 11 years of age, has a sensitivity and
specificity of 80 and 97 %, respectively, although in this age
range there were only five true positives. Both sensitivity
and specificity of the Ov-16 antibody test drop as a broader
age range is included in the analysis - down to 60 and 75 %,
respectively, against combined PCR- and microscopy-
confirmed active infection for all ages. In older age groups
anti-Ov16 antibody response is more reflective of exposure
than active infection, explaining why the specificity drops.
Anti-Ov16 antibody response was stronger in MF-positive
study participants than in MF-negative ones, suggesting
that antibody intensity may change temporally following
the clearance of MF infection. Longitudinal evidence of the
anti-Ov16 IgG4 response is needed to understand age-
seroprevalence curves in populations undergoing ivermec-
tin treatment. Furthermore, decreased intensity of the anti-
Ov16 response as measured by ELISA may be more likely
to be classified as negative. The classification by EM neces-
sarily yields a small group of results which have a higher
level of uncertainty surrounding the classification. If a sub-
group, of stringent uncertainty greater than 0.05 is filtered
from the dataset, removing 151 out of 2,003 results, the
performance of the Ov16 ELISA against active infection
determined by skin snip microscopy changes from 67.3 %
for the unfiltered set to 70.2 % for the filtered set, based on
49 and 47 MF-positive by skin snip microscopy, respect-
ively. The proportion of positive and negative-classified re-
sults is similar in the filtered and unfiltered sets. Given the
continuous output of ELISA, an ideal analysis method
would include an indeterminate results category. However,
Fig. 6 Seroprevalence against age, for the three village clusters described in Fig. 4. Two FOI curves were fitted to each cluster’s seroprevalence
plot. Graph a shows FOI fits for villages with < 15 % overall seroprevalence; b shows FOI fit for villages with 15–20 % seroprevalence; and c shows
FOI fits for villages with > 20 % seroprevalence. The bars for each point represent the standard deviation. The likelihood of change with respect to
age, informing the FOI fits, are shown below the seroprevalence plot for each respective village cluster
Table 3 2 × 2 contingency tables for anti-Ov16 antibody
sensitivity and specificity calculation against microfilarial (MF)
status, polymerase chain reaction (PCR) status, and the
composite MF + PCR all ages and under 11 year-old
Ov16 IgG4 all ages Ov16 IgG4 under age 11
Positive Negative Positive Negative
MF Positive 30 13 3 0
Negative 100 291 2 33
Total 130 304 5 33
PCR Positive 30 22 2 1
Negative 100 282 3 32
Total 130 304 5 33
MF + PCR Positive 39 26 4 1
Negative 91 278 1 32
Total 130 304 5 33
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more data is needed to understand how this indeterminate
group may be differentially populated in specific popula-
tions’ results or from classification using other methods of
data-fitting. Therefore, this study has instead included the
intensity of stratified Ov16 ELISA-positive results to
compare normalized ELISA signal between categories of
interest (Fig. 5).
Overall across all communities and all ages, the MF-
positive (as determined by microscopy) prevalence was
2.3 % and Ov16 seroprevalence was 19.7 %. In children
under 11, the MF prevalence and the seroprevalence were
1.6 and 3.6 %, respectively, but due to low recruitment of
this age group, the confidence intervals around the pro-
portions of positive MF or Ov16 serology are broad. The
all-age seroprevalence dynamic range across villages
allowed clustering based on village seroprevalence. In all
three clusters the seroprevalence increases with age range,
as shown previously [28]; however, a distinct two-phase
increment was observed. Therefore, fitting seroprevalence
against age with two FOI catalytic models provided better
fits than a single FOI assumption (data not shown), with
the younger age groups within each prevalence cluster ex-
periencing a lower seroconversion rate than the older age
groups. A previous FOI model for onchocerciasis included
a two-FOI consideration for settings with ongoing trans-
mission as a consequence of epidemiological data suggest-
ing that people under the age of ten years were at lower
risk of infection than those older than ten years of age
[42]. A dual FOI model applied to trachoma sero-
surveillance showed that the age at which the models
transitioned coincided with the initiation of MDA activ-
ities for trachoma [37]. In the data from this study for sur-
veillance in Togo, the dual seroconversion rates within
each age range could be due to either a noticeable de-
crease in transmission at a particular point in time
reflected by the transition age on the fits, or a reflection of
a higher exposure risk to infection for the older age
groups. These are not mutually exclusive explanations.
However, the more constant microfilaria prevalence across
all age groups suggests that seroconversion rate changes
are indicative of events leading to a change in transmis-
sion rates at a village level. Interestingly, the transition age
decreases from 25 to 20 to 16 years of age from the low to
medium to high prevalence cluster of villages, respectively.
Understanding the transition between the two-phases of
FOI curves and their relationship to the true transmission
in settings approaching elimination but that were highly
endemic in the recent past will be important in under-
standing if there is benefit to extend sero-surveillance to a
broader age group. To support this understanding, there
is a need to collect all-age seroprevalence data from more
settings in Africa.
Clustering the villages by all-age seroprevalence posi-
tively coincided with relative seroconversion rates such
that the village cluster with the lowest seroprevalence
also had the lowest seroconversion rate in the younger
age group. While further studies are required to validate
the utility of sero-surveillance of older children and
adults, this analysis suggests that seroprevalence over a
broad age range is useful to stratify relative progression
toward elimination across multiple villages within given
foci. This may provide a useful means to identify villages
that are less responsive for any given reason to current
interventions and may require more specific interven-
tions, such as vector control, increased resources for
coverage, or twice-a-year MDA. Seroprevalence is in-
creasingly being used to generate models for estimation
of transmission dynamics in near-elimination contexts,
most notably in malaria [43–46].
Conclusions
Ov16 antibody response may be a good marker for ac-
tive infection in children under the age of 11 years in
this population. Broadening the age range in seropreva-
lence studies provides valuable additional information
on the progression toward achieving elimination in a
given setting. Inclusion of a broader age range increases
the number of data points per village and allows better
stratification at an individual village level to estimate
progression towards elimination based on seroconver-
sion rates. This in turn can inform where and when
targeted interventions are required. Similar studies need
to be performed in other settings in OCP and APOC
countries to develop a better understanding of how to
interpret cross-sectional all-age seroprevalence data.
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